Table 2.
Laboratory findings and circulating level of EPCs between IS patients with and without EPO treatment
| Variables | Group 1† (n = 83) | Group 2† (n = 84) | P-value* |
|---|---|---|---|
| Circulating level of EPCs at 48 h | |||
| CD31/CD34 (%) | 1.65 ± 0.91 | 1.75 ± 1.03 | 0.530 |
| CD62E/CD34 (%) | 1.21 ± 0.86 | 1.16 ± 0.76 | 0.704 |
| KDR/CD34 (%) | 1.34 ± 0.76 | 1.37 ± 0.89 | 0.791 |
| Circulating level of EPCs on day 7 | |||
| CD31/CD34 (%) | 1.52 ± 1.06 | 1.48 ± 0.89 | 0.801 |
| CD62E/CD34 (%) | 1.11 ± 0.76 | 1.14 ± 0.75 | 0.855 |
| KDR/CD34 (%) | 1.16 ± 0.70 | 1.24 ± 0.80 | 0.523 |
| Circulating level of EPCs on day 21 | |||
| CD31/CD34 (%) | 2.28 ± 1.48 | 1.64 ± 0.79 | 0.002 |
| CD62E/CD34 (%) | 1.50 ± 1.13 | 1.14 ± 0.72 | 0.030 |
| KDR/CD34 (%) | 1.81 ± 1.25 | 1.22 ± 0.71 | 0.001 |
| RBC count (×106/mL) on day 21 | 4.56 ± 0.73 | 4.62 ± 1.16 | 0.719 |
| Hemoglobin (g/dL) on day 21 | 13.7 ± 1.9 | 13.8 ± 3.3 | 0.746 |
| Hematocrit (%) on day 21 | 41.0 ± 5.4 | 39.9 ± 6.4 | 0.309 |
| WBC count (×103/mL) on day 21 | 7.68 ± 6.30 | 7.27 ± 2.47 | 0.645 |
*: by t-test.
†: group 1 = with EPO treatment; group 2 = without EPO treatment.
EPC = endothelial progenitor cell; EPO = erythropoietin; RBC = red blood cell; WBC = white blood cell.